antibody-drug conjugate

  •   George Lundberg, MD

    This academic review paper from Blood Cancer Journal outlines many recent advances in the treatment of Hodgkin lymphoma, including for the 15-30% of patients who do not respond or relapse after conventional treatment.

    .

  •  

    New Research on Triple Negative Breast Cancer Emerges at ASCO 2016

    Emma Shtivelman, PhD

    The American Society of Clinical Oncology (ASCO) meeting of 2016 is behind us, but oncologists, patients, and journalists are still analyzing the most interesting presentations made there. Below, we describe some of the more prominent results in triple negative breast cancer (TNBC), both promising and disappointing.

  •  

    Small Cell Lung Cancer at ASCO: Some Welcome News

    Emma Shtivelman, PhD

    Small cell lung cancer (SCLC) is a fatal disease that has not seen new drug approvals for the last 17 years. Considering the relative success of ‘immune checkpoint inhibitors’ in non-small cell lung cancer (NSCLC), it is not surprising that several abstracts recently presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting were devoted to clinical trials testing these trendy, immune… Read more »